This review article discusses the potential use of growth-hormone-releasing hormone (GHRH) antagonists in cancer therapy. GHRH antagonists have been shown to inhibit the growth of various human cancer lines, including breast, ovarian, prostate, lung, brain, and other cancers, in xenograft models. The therapeutic action is primarily through blocking the autocrine/paracrine
